维持治疗期间更换卡介苗菌株是否影响非肌层浸润性膀胱癌的结局?
该回顾性研究纳入2012年1月至2019年5月接受BCG治疗的279例患者,比较维持治疗期间使用单一BCG菌株(225例,80.6%)与多种BCG菌株(54例,19.4%)患者的无复发生存率和无进展生存率。经匹配分析,两组在无复发生存率和无进展生存率上均无显著差异,不良反应也无统计学差异。结论认为因诱导菌株不可获得而更换BCG菌株不会降低治疗效果,可安全使用任何可用菌株继续治疗。
要点
- 维持期更换BCG菌株与单一菌株相比,无复发生存和无进展生存无显著差异。
- 两组BCG治疗相关不良反应发生率无统计学差异。
- 诱导菌株不可及时,可安全换用其他可用菌株继续治疗。
核心结论
- 因诱导菌株不可获得而更换BCG菌株不会降低治疗效果。
- 无法获得起始BCG菌株时,可安全使用任何可用菌株继续治疗。
研究设计与样本
- 回顾性研究,纳入2012年1月至2019年5月接受BCG治疗的279例患者。
- 按维持治疗期间使用单一BCG菌株(Group-1)与多种BCG菌株(Group-2)分组,并进行匹配分析。
主要发现
- 225例(80.6%)使用单一BCG菌株,54例(19.4%)使用多种BCG菌株。
- 总体复发86例(30.8%),进展38例(13.6%)。
关键数值与推荐
- 主要终点为无复发生存率和无进展生存率。
- 采用Kaplan-Meier法估计无复发生存率和无进展生存率。
- 不良反应差异采用卡方检验评估。
临床怎么用
- 当起始BCG菌株不可获得时,可换用其他可用菌株继续维持治疗,无需中断。
局限性
- 回顾性研究设计。
- 样本量有限(共279例,多菌株组仅54例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the patients who have received 1 type of BCG strain during maintenance therapy with patients treated with multiple BCG strains. MATERIAL AND METHODS: We reviewed 279 patients treated with BCG between January 2012 and May 2019, retrospectively. The primary endpoints of the study were recurrence-free survival (RFS) and progression-free survival (PFS) rates among patients receiving same BCG strain (Group-1) and multiple BCG strains (Group-2). Matching analysis was performed to balance the groups. The Kaplan-Meier method was used for estimating RFS and PFS. The difference between the 2 groups in terms of adverse effects was evaluated using the chi-square test. RESULTS: A total of 225 (80.6 %) patients were treated with single BCG strain, and 54 (19.4 %) were treated with multiple BCG strains. Overall, recurrence and progression was observed in 86 (30.8%) and 38 (13.6%) patients, respectively. There was no significant difference between the 2 groups in terms of recurrence-free survival and progression-free survival on both without matching and with propensity score match analysis (log rank; P=.760 and P=.559, P=.533 and P=0509 for non-match and matched analysis respectively). Most of the patients in both groups experienced BCG therapy related side effects, but there was no statistically significant difference between groups (P=.235/.833). CONCLUSIONS: Switching the BCG strain because of unavailability of the induction strain does not decrease the effectiveness of the treatment. When it is not possible to reach the starting BCG strain, treatment can be safely continued with any available strain.
引用
- Süer E, Karaburun MC, Babayiğit M, et al. Does Switching Bacillus Calmette-Guerin Strains During Maintenance Therapy Affect the Outcome in Non-Muscle Invasive Bladder Cancer? Urology. 2021. PMID: 34428538. doi:10.1016/j.urology.2021.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。